Drugs / nL-FLVC-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06565572 | Aug 2023 → Aug 2024 overdue | posterior column ataxia-retinitis pigmentosa syndrome | University of Colorado, Denver | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-FLVC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06565572 ↗ |
| Modality | Antisense oligonucleotide | “nL-FLVC-001 is an antisense oligonucleotide” NCT06565572 ↗ |
| Route | Intravitreal | “injected into the vitreous” NCT06565572 ↗ |